Next Article in Journal
Pharmacological Activation of p53 during Human Monocyte to Macrophage Differentiation Attenuates Their Pro-Inflammatory Activation by TLR4, TLR7 and TLR8 Agonists
Previous Article in Journal
FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo
Article

Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice

1
Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Korea
2
Genome and Company, Pangyo-ro 255, Bundang-gu, Seoungnam 13486, Korea
3
Severance Biomedical Science Institute, BK21 PLUS Project for Medical Science, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Luca Roncucci
Cancers 2021, 13(5), 957; https://doi.org/10.3390/cancers13050957
Received: 19 January 2021 / Revised: 15 February 2021 / Accepted: 19 February 2021 / Published: 25 February 2021
The efficacy of cancer therapeutics depends on several factors, including the tumor genome, epigenome, and transcriptome. In addition, the tumor microenvironment, which consists mainly of immune cells, can influence cancer treatment outcomes. Hence, effectively leveraging host immunity is an important aspect of cancer treatment strategies. The human gut microbiome is involved in the regulation of the immune responses and affects the efficacy of chemotherapeutic and immunotherapeutic agents, including oxaliplatin, cyclophosphamide, and immune checkpoint inhibitors. This study reveals an additional dimension to the Bifidobacterium strain-specific determination of anti-cancer therapeutic efficacy using flow cytometry and transcriptome analysis of bacterial strain-fed mice and bacterial whole transcriptome analysis. We hope that our work will contribute to leveraging the gut microbiome to improve anti-cancer therapies.
Colorectal cancer (CRC) is among the leading causes of cancer-related death in the world. The development of CRC is associated with smoking, diet, and microbial exposure. Previous studies have shown that dysbiosis of the gut microbiome affects cancer development, because it leads to inflammation and genotoxicity. Supplementation with specific microbiota induces anti-tumor effects by enhancing of anti-tumor immunity. Here, we observed that supplementation with either of two B. breve strains reduces tumor growth in MC38 colon carcinoma-bearing mice. Interestingly, only one B. breve strain boosted the efficacy of cancer therapeutics, including oxaliplatin and PD-1 blockade. Extensive immune profiling and transcriptomic analysis revealed that the boosting B. breve strain augments lymphocyte-mediated anti-cancer immunity. Our results suggest that supplementation with B. breve strains could potentially be used as a strategy to enhance the efficacy of CRC therapeutics. View Full-Text
Keywords: colorectal cancer; Bifidobacterium breve; oxaliplatin; PD-1 blockade; transcriptomic analysis colorectal cancer; Bifidobacterium breve; oxaliplatin; PD-1 blockade; transcriptomic analysis
Show Figures

Figure 1

MDPI and ACS Style

Yoon, Y.; Kim, G.; Jeon, B.-N.; Fang, S.; Park, H. Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice. Cancers 2021, 13, 957. https://doi.org/10.3390/cancers13050957

AMA Style

Yoon Y, Kim G, Jeon B-N, Fang S, Park H. Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice. Cancers. 2021; 13(5):957. https://doi.org/10.3390/cancers13050957

Chicago/Turabian Style

Yoon, Youngmin, Gihyeon Kim, Bu-Nam Jeon, Sungsoon Fang, and Hansoo Park. 2021. "Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice" Cancers 13, no. 5: 957. https://doi.org/10.3390/cancers13050957

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop